The reduction in infarct and edema volume in the CasRx-Ripk1-Nsf group following tMCAO suggests that the knockdown of Ripk1 and Nsf provides a certain level of protection against ischemia brain injury. This evidence concerns the gene RIPK1 and ischemia.